April 2015

New Product - Mycamine

Mycamine (micafungin (as sodium)) is a member of the echinocandin lipopeptide family and inhibits noncompetitively the synthesis of 1,3‑ß‑D‑glucan, an essential component of fungal cell walls which is not present in mammalian cells. Mycamine is indicated for the treatment of invasive candidiasis in children and adults; treatment of oesophageal candidiasis in adults, adolescents ≥ 16 years of age and elderly patients for whom intravenous therapy is appropriate; and in the prophylaxis of Candida infection in children and adult patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/microL) for 10 or more days. Mycamine is available as a powder for injection in a 10 mL single use glass vial containing 50 mg of micafungin (equivalent to 50.86 mg micafungin sodium) or 100 mg of micafungin (equivalent to 101.73 mg micafungin sodium) in packs of 1’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629